• IN EDITION MEDICUS WAS PUBLISHED

    MULTIDISCIPLINARY APPROACH to Oesophageal and gastric cancer

     

    EDITOR: RADKA OBERMANNOVA
    ASSOCIATE EDITORS: FLORIAN LORDICK, LUBOS PETRUZELKA

    This book aims at highlighting the present and very dynamic development in the field of pper GI cancers. Oesophageal and gastric cancer are diseases with poor prognosis. Looking back to ous efforts to treat these serious malignancies have been dated already to the ancient periods. The introductory chapter of this issue is therefore dedicated to history of gastric cancer that is tightly connected to history of development of surgical techniques. Surgery remains the basic cornerstone of the treatment of localized oesophageal and gastric cancer and chapters attributed to surgery delineate the sustained development either in classical surgical techniques but also an implementation of new technologies, especially robotic surgery into clinical practice.

    Price: 790 CZK (31EUR),  Pre-order: info@currentmedia.cz
     

    MORE INFORMATION 

    Obrázek

     

Actual articles

A patient with metastatic colorectal cancer who prefers outpatient treatment - case report

01/2020 MUDr. Jiří Tomášek, Ph.D.
We present a case report of a 75-year-old woman who has been treated for 4.5 years for metastatic colorectal cancer and emphasizes out-patient treatment, which should not significantly affect her life.
ENTIRE ARTICLE

Rechallenge of EGFR inhibitors in the treatment of metastatic colorectal cancer - case report

01/2020 MUDr. Hana Korunková
A case of a patient who has been treated for metastatic colorectal cancer for six years will be presented. Patient was treated with six lines of systemic treatment and two local liver treatments. All available cytostatics indicated for the diagnosis except for capecitabine, targeted therapies except bevacizumab were used in systemic treatment, and the rechallenge of the EGFR inhibitor was used.
ENTIRE ARTICLE

Patient with NSCLC and brain metastases and positive reassortment ALK treated with alectinib - case report

01/2020 MUDr. Leona Koubková
A better understanding of the molecular biology of tumors and the expanding possibilities of their genotyping lead to the enhancement of precise medicine, which is based on the pursuit of individualized treatment. It is primarily the genetic changes of the tumor that help us to predict the response to molecularly targeted treatment. These also include rearrangement of the ALK (anaplastic lymphoma kinase) gene in NSCLC (non-small cell lung cancer), which predicts the efficacy of ALK inhibitors, which significantly improve treatment outcomes in patients with this severe disease. Alectinib, the current standard for the first line ALK-positive NSCLC treatment, is a highly selective and potent inhibitor of ALK and RET (rearranged during transfection) tyrosine kinase and has been set to be reimbursed in the 1st line of treatment in the Czech Republic from 1st November 2019.
ENTIRE ARTICLE